Felice C Lightstone
Overview
Explore the profile of Felice C Lightstone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
1335
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maciag A, Stice J, Wang B, Sharma A, Chan A, Lin K, et al.
Cancer Discov
. 2024 Dec;
15(3):578-594.
PMID: 39642212
Approved inhibitors of KRASG12C prevent oncogenic activation by sequestering the inactive, GDP-bound (OFF) form rather than directly binding and inhibiting the active, GTP-bound (ON) form. This approach provides no direct...
2.
Georgouli K, Stephany R, Tempkin J, Santiago C, Aydin F, Heimann M, et al.
J Chem Theory Comput
. 2024 Oct;
20(20):8795-8806.
PMID: 39388723
Resolving the intricate details of biological phenomena at the molecular level is fundamentally limited by both length- and time scales that can be probed experimentally. Molecular dynamics (MD) simulations at...
3.
Morstein J, Bowcut V, Fernando M, Yang Y, Zhu L, Jenkins M, et al.
Cell
. 2024 Sep;
187(22):6379-6392.e17.
PMID: 39255801
The family of Ras-like GTPases consists of over 150 different members, regulated by an even larger number of guanine exchange factors (GEFs) and GTPase-activating proteins (GAPs) that comprise cellular switch...
4.
Shrestha R, Carpenter T, Van Q, Agamasu C, Tonelli M, Aydin F, et al.
Commun Biol
. 2024 Apr;
7(1):445.
PMID: 38605143
No abstract available.
5.
Shrestha R, Carpenter T, Van Q, Agamasu C, Tonelli M, Aydin F, et al.
Commun Biol
. 2024 Feb;
7(1):242.
PMID: 38418613
The oncogene RAS, extensively studied for decades, presents persistent gaps in understanding, hindering the development of effective therapeutic strategies due to a lack of precise details on how RAS initiates...
6.
Sharma A, Pei J, Yang Y, Dyba M, Smith B, Rabara D, et al.
J Biol Chem
. 2024 Jan;
300(2):105650.
PMID: 38237681
Individual oncogenic KRAS mutants confer distinct differences in biochemical properties and signaling for reasons that are not well understood. KRAS activity is closely coupled to protein dynamics and is regulated...
7.
Stevenson G, Kirshner D, Bennion B, Yang Y, Zhang X, Zemla A, et al.
J Chem Inf Model
. 2023 Oct;
63(21):6655-6666.
PMID: 37847557
Protein-ligand interactions are essential to drug discovery and drug development efforts. Desirable on-target or multitarget interactions are the first step in finding an effective therapeutic, while undesirable off-target interactions are...
8.
Fan Y, Allen J, McLoughlin K, Shi D, Bennion B, Zhang X, et al.
Artif Intell Chem
. 2023 Aug;
1(1).
PMID: 37583465
Neural Network (NN) models provide potential to speed up the drug discovery process and reduce its failure rates. The success of NN models requires uncertainty quantification (UQ) as drug discovery...
9.
Stroet M, Caron B, Engler M, van der Woning J, Kauffmann A, van Dijk M, et al.
J Comput Aided Mol Des
. 2023 Jun;
37(8):357-371.
PMID: 37310542
An Online tool for Fragment-based Molecule Parametrization (OFraMP) is described. OFraMP is a web application for assigning atomic interaction parameters to large molecules by matching sub-fragments within the target molecule...
10.
Ingolfsson H, Bhatia H, Aydin F, Oppelstrup T, Lopez C, Stanton L, et al.
J Chem Theory Comput
. 2023 Apr;
19(9):2658-2675.
PMID: 37075065
Interdependence across time and length scales is common in biology, where atomic interactions can impact larger-scale phenomenon. Such dependence is especially true for a well-known cancer signaling pathway, where the...